文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

肝硬化患者念珠菌血症与腹腔内念珠菌病的临床特征及死亡预测因素:一项多中心研究

Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.
PubMed 文献 · Intensive Care Med · 2017-03-07
一句话结论肝硬化患者念珠菌血症与腹腔内念珠菌病30天死亡率为35.3%,念珠菌血症与脓毒性休克为独立死亡因素,充分抗真菌治疗与生存获益相关。

该多中心跨国回顾性研究纳入2011至2013年14家欧洲医院连续241例肝硬化合并念珠菌血症(169例)或腹腔内念珠菌病(72例)成年患者。86.3%的感染为院内获得,50.2%发生在ICU,就诊时脓毒性休克占34.9%。白色念珠菌最常见(54.4%),光滑念珠菌(14.5%)和近平滑念珠菌(14.1%)次之。30天总死亡率为35.3%,多变量分析显示念珠菌血症(OR 2.2,95%CI 1.2-4.5)和脓毒性休克(OR 3.2,95%CI 1.7-6)为独立死亡因素,充分抗真菌治疗(OR 0.4,95%CI 0.3-0.9)与生存获益相关。

要点

  • 肝硬化患者念珠菌血症与腹腔内念珠菌病30天死亡率达35.3%,念珠菌血症(OR 2.2,95%CI 1.2-4.5)和脓毒性休克(OR 3.2,95%CI 1.7-6)为独立死亡因素。
  • 充分抗真菌治疗与生存获益相关(OR 0.4,95%CI 0.3-0.9),提示及时恰当的抗真菌治疗可能改善预后。
  • 86.3%的念珠菌感染为院内获得,50.2%发生在ICU,肝硬化患者入住ICU时需警惕念珠菌感染。
  • 就诊时脓毒性休克占34.9%,脓毒性休克是独立死亡因素,需早期识别与处理。
  • 白色念珠菌最常见(54.4%),但光滑念珠菌(14.5%)和近平滑念珠菌(14.1%)在肝病患者中呈增加趋势。

适用人群与场景

  • 2011至2013年14家欧洲医院连续纳入的成年肝硬化合并念珠菌血症或腹腔内念珠菌病患者,共241例(念珠菌血症169例,腹腔内念珠菌病72例)。

处置流程与药物剂量

  • 充分抗真菌治疗与生存获益相关(OR 0.4,95%CI 0.3-0.9),原文未给出具体药物、剂量及疗程。

红旗征与不能漏的情况

  • 就诊时脓毒性休克占34.9%(84/241),脓毒性休克为独立死亡因素(OR 3.2,95%CI 1.7-6)。
  • 念珠菌血症为独立死亡因素(OR 2.2,95%CI 1.2-4.5),肝硬化患者出现念珠菌血症提示预后不良。

研究设计与关键结果

  • 多中心跨国回顾性研究,纳入14家欧洲医院2011至2013年连续241例肝硬化合并念珠菌血症或腹腔内念珠菌病成年患者。
  • 念珠菌感染86.3%(208/241)为院内获得,50.2%(121/241)发生在ICU;就诊时发热60.6%(146/241),脓毒性休克34.9%(84/241)。
  • 白色念珠菌最常见(131例,54.4%),光滑念珠菌35例(14.5%),近平滑念珠菌34例(14.1%)。
  • 30天总死亡率为35.3%。
  • 多变量分析:念珠菌血症OR 2.2(95%CI 1.2-4.5),脓毒性休克OR 3.2(95%CI 1.7-6),充分抗真菌治疗OR 0.4(95%CI 0.3-0.9)。

证据类型、等级与局限

  • 证据类型:多中心跨国回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 肝硬化患者院内出现念珠菌血症或腹腔内念珠菌病时死亡风险高,尤其合并脓毒性休克者(OR 3.2,95%CI 1.7-6),应重视病情评估。
  • 充分抗真菌治疗与生存获益相关(OR 0.4,95%CI 0.3-0.9),作者认为充分抗真菌治疗可改善预后。
  • 肝病患者中光滑念珠菌和近平滑念珠菌检出比例增加,经验性抗真菌治疗时需考虑覆盖非白色念珠菌。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The aim of the study was to describe the characteristics of cirrhotic patients with candidemia and intra-abdominal candidiasis (IAC) and to evaluate the risk factors associated with 30-day mortality.

METHODS: A multicenter multinational retrospective study including all consecutive episodes of candidemia and IAC in adult patients with liver cirrhosis in 14 European hospitals during the period 2011-2013 was performed.

RESULTS: A total of 241 episodes (169 candidemia, 72 IAC) were included. Most Candida infections were acquired in hospital (208, 86.3%), mainly in the intensive care unit (ICU) (121, 50.2%). At clinical presentation, fever was seen in 60.6% of episodes (146/241) and septic shock in 34.9% (84/241). C. albicans was the most common species (found in 131 episodes, 54.4%), followed by C. glabrata (35, 14.5%) and C. parapsilosis (34, 14.1%). Overall, the 30-day mortality was 35.3%. Multivariable analysis identified candidemia (OR 2.2, 95% CI 1.2-4.5) and septic shock (OR 3.2, 95% CI 1.7-6) as independent factors associated with 30-day mortality. Adequate antifungal treatment (OR 0.4, 95% CI 0.3-0.9) was associated with survival benefit.

CONCLUSIONS: A shift towards increasing prevalence of C. glabrata and C. parapsilosis species in patients with liver disease was documented. Candidemia and IAC were associated with significant mortality in cirrhotic patients. Thirty-day mortality was associated with candidemia and severe clinical presentation, whereas adequate antifungal treatment improved the prognosis.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bassetti M, Peghin M, Carnelutti A, et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Med. 2017. PMID: 28271321. doi:10.1007/s00134-017-4717-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。